anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Callout

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 96,741
Current window 75,391-75,420
Pages 3,225
Rows per page 30
Component: Calloutclear collectionreset all
18 30 60

Component

75,391-75,420 of 96,741

filter-aware
64
The slide uses direct quotes from an expert to undermine the commercial viability and clinical efficacy of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
65
The slide uses direct quotes from a trial investigator to undermine the drug's efficacy and safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
66
This slide is part of a series of 'investigator' profiles used to build a case against a company's clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
67
The slide presents critical expert feedback on drug formulation and safety protocols.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
68
The slide uses a 'villain' or 'expert critic' framing to undermine the credibility of a clinical trial and its associated drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
69
The slide uses direct quotes from an expert to undermine the value proposition of the subject company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
70
The slide uses a series of bullet points to contrast public posturing with private admissions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
71
The slide uses specific quotes from an investigator to undermine the validity of clinical trial results and highlight potential adverse events.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
73
The slide emphasizes the credibility and breadth of the expert sample to validate the subsequent findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
74
The slide uses direct quotes to undermine the credibility of the drug's approval and market demand.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
75
The slide uses direct quotes from an expert consultation to undermine the company's product launch and clinical efficacy claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
76
The slide uses a direct quote to highlight medical risks that could limit the drug's market potential.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
77
The slide serves as a negative testimonial/expert critique of the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
78
The slide uses direct quotes to highlight a lack of industry awareness and clinical skepticism regarding the drug's mechanism and efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
79
The slide uses direct quotes to highlight the expert's negative sentiment and lack of awareness/enthusiasm for the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
80
The slide highlights the risk of off-label substitution for the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
81
The slide captures qualitative feedback from a medical expert, highlighting low adoption rates and negative sentiment toward the company's sales approach.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
82
The slide uses direct quotes to undermine the company's marketing claims and highlight physician concerns regarding side effects like diabetes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
83
The slide uses direct quotes from an expert to undermine the company's clinical narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
84
The slide uses direct quotes to undermine the company's marketing claims about drug efficacy and differentiation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
85
The slide uses direct quotes to highlight the physician's lack of confidence in the drug and his perception of external pressure from patient advocacy groups.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
86
The slide uses direct quotes to undermine the credibility of the drug's clinical narrative and the company's influence on investigators.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
87
The slide uses direct quotes to validate the activist's thesis regarding the drug's risks and market limitations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
88
The slide highlights the gap between physician prescribing behavior (driven by patient pressure) and their actual clinical belief in the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
89
This slide presents qualitative interview data from a medical expert to undermine the credibility of a drug and a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
90
The slide uses direct quotes to frame the expert's skepticism regarding the company's marketing and clinical rationale.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
91
The slide uses direct quotes to highlight expert skepticism regarding safety, efficacy, and pricing.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
92
The slide presents qualitative expert feedback from a medical professional regarding drug safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
93
The slide presents qualitative feedback from a medical expert, highlighting concerns about diabetes risk and comparing the drug to the Aduhelm controversy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
94
This slide presents qualitative feedback from a medical expert, highlighting significant barriers to adoption for the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit